These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 8078734)

  • 1. Crossover of placebo patients to intravenous immunoglobulin confirms efficacy for prophylaxis of bacterial infections and reduction of hospitalizations in human immunodeficiency virus-infected children. The National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group.
    Mofenson LM; Moye J; Korelitz J; Bethel J; Hirschhorn R; Nugent R
    Pediatr Infect Dis J; 1994 Jun; 13(6):477-84. PubMed ID: 8078734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylactic intravenous immunoglobulin in HIV-infected children with CD4+ counts of 0.20 x 10(9)/L or more. Effect on viral, opportunistic, and bacterial infections. The National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group.
    Mofenson LM; Moye J; Bethel J; Hirschhorn R; Jordan C; Nugent R
    JAMA; 1992 Jul 22-29; 268(4):483-8. PubMed ID: 1352363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. Pediatric AIDS Clinical Trials Group.
    Spector SA; Gelber RD; McGrath N; Wara D; Barzilai A; Abrams E; Bryson YJ; Dankner WM; Livingston RA; Connor EM
    N Engl J Med; 1994 Nov; 331(18):1181-7. PubMed ID: 7935655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of intravenous immunoglobulin (IVIG) on CD4+ lymphocyte decline in HIV-infected children in a clinical trial of IVIG infection prophylaxis. The National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group.
    Mofenson LM; Bethel J; Moye J; Flyer P; Nugent R
    J Acquir Immune Defic Syndr (1988); 1993 Oct; 6(10):1103-13. PubMed ID: 8105072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined therapy in human immunodeficiency virus-infected children--a 4-year experience.
    Güngör T; Funk M; Linde R; Kynast I; Allendorf A; Lotz C; Ehrenforth S; Hofmann D; Kornhuber B; Kreuz W
    Eur J Pediatr; 1993 Aug; 152(8):650-4. PubMed ID: 8104791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics of acute pneumonia in human immunodeficiency virus-infected children and association with long term mortality risk. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group.
    Mofenson LM; Yogev R; Korelitz J; Bethel J; Krasinski K; Moye J; Nugent R; Rigau-Perez JG
    Pediatr Infect Dis J; 1998 Oct; 17(10):872-80. PubMed ID: 9802627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of atovaquone and azithromycin with trimethoprim-sulfamethoxazole for the prevention of serious bacterial infections in children with HIV infection.
    Hughes WT; Dankner WM; Yogev R; Huang S; Paul ME; Flores MA; Kline MW; Wei LJ;
    Clin Infect Dis; 2005 Jan; 40(1):136-45. PubMed ID: 15614703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous immune globulin for the prevention of infections in children with symptomatic human immunodeficiency virus infection.
    Mofenson LM; Moye J
    Pediatr Res; 1993 Jan; 33(1 Suppl):S80-7; discussion S87-9. PubMed ID: 8433880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pneumocystis prophylaxis and survival in patients with advanced human immunodeficiency virus infection treated with zidovudine. The Zidovudine Epidemiology Group.
    Chaisson RE; Keruly J; Richman DD; Moore RD
    Arch Intern Med; 1992 Oct; 152(10):2009-13. PubMed ID: 1417373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous immune globulin for prevention of bacterial infections in pediatric AIDS patients.
    Crow ME
    Am J Health Syst Pharm; 1995 Apr; 52(8):803-11. PubMed ID: 7634115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful prophylaxis against Pneumocystis carinii pneumonia in HIV-infected children using smaller than recommended dosages of trimethoprim-sulfamethoxazole.
    Fisher RG; Nageswaran S; Valentine ME; McKinney RE
    AIDS Patient Care STDS; 2001 May; 15(5):263-9. PubMed ID: 11530767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021.
    Hardy WD; Feinberg J; Finkelstein DM; Power ME; He W; Kaczka C; Frame PT; Holmes M; Waskin H; Fass RJ
    N Engl J Med; 1992 Dec; 327(26):1842-8. PubMed ID: 1448121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sinusitis in children infected with human immunodeficiency virus: clinical characteristics, risk factors, and prophylaxis. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group.
    Mofenson LM; Korelitz J; Pelton S; Moye J; Nugent R; Bethel J
    Clin Infect Dis; 1995 Nov; 21(5):1175-81. PubMed ID: 8589139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human immunodeficiency virus infection in children.
    Hoernle EH; Reid TE
    Am J Health Syst Pharm; 1995 May; 52(9):961-79. PubMed ID: 7641035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of primary chemoprophylaxis against Pneumocystis carinii pneumonia during the first year of life in infants infected with human immunodeficiency virus type 1.
    Rigaud M; Pollack H; Leibovitz E; Kim M; Persaud D; Kaul A; Lawrence R; John DD; Borkowsky W; Krasinski K
    J Pediatr; 1994 Sep; 125(3):476-80. PubMed ID: 7915306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose trimethoprim-sulfamethoxazole prophylaxis for toxoplasmic encephalitis in patients with AIDS.
    Carr A; Tindall B; Brew BJ; Marriott DJ; Harkness JL; Penny R; Cooper DA
    Ann Intern Med; 1992 Jul; 117(2):106-11. PubMed ID: 1351371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intermittent trimethoprim-sulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of Pneumocystis pneumonia and toxoplasmosis in patients infected with HIV.
    Podzamczer D; Salazar A; Jiménez J; Consiglio E; Santín M; Casanova A; Rufí G; Gudiol F
    Ann Intern Med; 1995 May; 122(10):755-61. PubMed ID: 7717598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trimethoprim-sulfamethoxazole oral desensitization in hemophiliacs infected with human immunodeficiency virus with a history of hypersensitivity reactions.
    Kletzel M; Beck S; Elser J; Shock N; Burks W
    Am J Dis Child; 1991 Dec; 145(12):1428-9. PubMed ID: 1688295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TSCQ study: a randomized, controlled, open-label trial of daily trimethoprim-sulfamethoxazole or weekly chloroquine among adults on antiretroviral therapy in Malawi: study protocol for a randomized controlled trial.
    Laurens MB; Mungwira RG; Nyirenda OM; Divala TH; Kanjala M; Muwalo F; Mkandawire FA; Tsirizani L; Nyangulu W; Mwinjiwa E; Taylor TE; Mallewa J; Blackwelder WC; Plowe CV; Laufer MK; van Oosterhout JJ
    Trials; 2016 Jul; 17(1):322. PubMed ID: 27431995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma.
    Chapel HM; Lee M; Hargreaves R; Pamphilon DH; Prentice AG
    Lancet; 1994 Apr; 343(8905):1059-63. PubMed ID: 7909099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.